Cardiovascular disease (CVD) Segment has the Largest Share of Type in the Europe Cardiometabolic Diseases Market during 2021–2028

According to our latest study on “Europe Cardiometabolic Diseases Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Dosage, Route of Administration, End User, and Distribution Channel,” the market is projected to reach US$ 33,963.6 million by 2028 from US$ 26,717.5 million in 2021; it is expected to grow at a CAGR of 3.5% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing prevalence of cardiometabolic diseases, and innovation in cardiometabolic diseases therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market to a certain extent.

In Europe, the COVID-19 pandemic has significant implications on the cardiovascular care of patients. Those living with pre-existing cardiovascular diseases have an increased risk of health deterioration and death on contracting COVID-19. Prevention, diagnosis, and treatment services for CVDs have been severely disrupted since the COVID-19 pandemic. According to MedTech Europe, around 95% of all COVID-19 deaths had at least one underlying condition, with cardiovascular disease being the leading comorbidity (65%). Also, around 50% decrease in the number of people visiting at hospitals and other health care facilities with symptoms of heart attacks or stroke, creating a significant backlog of patients with severe health conditions. Also, a reduction in emergency department attendances for cardiac presentation compared with the previous year dropped by between 31% and 88% after a lockdown in the UK, negatively impacting the market growth. The pandemic has significantly impacted the market in the short term; however, the market will grow at a moderate pace in the forecast period.

Based on type, the Europe cardiometabolic diseases market is bifurcated into cardiovascular disease, type 2 diabetes, hypertension, and obesity. In 2021, the cardiovascular disease segment is likely to account for the highest share of the market. Growth of this segment is majorly attributed to the increasing hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents. Furthermore, the increasing R&D activities in the pharmaceutical’s companies, ageing population is likely to create opportunity in the forecast year.

Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., and Kowa Company, Ltd. are among the leading companies in the Europe cardiometabolic diseases market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for cardiometabolic diseases market is bifurcated into type, treatment, dosage, route of administration, end user, and distribution channel. Based on type, the Europe cardiometabolic diseases market is segmented into cardiovascular disease (CVD), type 2 diabetes, hypertension, and obesity. Based on treatment, the cardiometabolic diseases market is segmented into ACE inhibitors, diuretics, glucophage, and others. Based on dosage, the cardiometabolic diseases market is segmented into tablet, and injection. Based on route of administration, the cardiometabolic diseases market is segmented into oral, and intravenous. Based on end user, the cardiometabolic diseases market is segmented into hospital, clinic, and homecare settings. Based on distribution channel, the cardiometabolic diseases market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the cardiometabolic diseases market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com